PRCA facts Flashcards
Transient aplastic crisis
Parvo B19
Predisposing factors of immunodeficiency (HIV/SCID) or hereditary hemolytic anemia (Spherocytosis…)
In immunodeficiency may need Tx with IVIG
In congenital hemolysis syndromes- no need for Tx
Diamond- Blackfan anemia
Hereditary PRCA
Good syndrome
Hypoglobulinemia and thymoma
May present with PRCA, LGL
Diseases associated with PRCA
T-LGL
Lymophoma (CLL)
Thymoma
Good syndrome
Post ABO incompatible all transplant
BM diagnosis of PRCA
Erythroid hypoplasia(<1-5%)
With giant erythroblast
Vacualted
DD of PRCA
Copper deficiency
MDS
AA
w/u of PRCA
Anemiogram including EPO and Coombs
Erytorocyte adenosine deaminase and genetic testing for Diamond-Blackfan anemia
FACS, PCR TCR and STAT3 mutation for LGL
ANA/RF
PEP/IEP/FLC
Parvo, HBV, HCV, HIV, EBV, CMV
BMB
CT scan of chest for thymoma
Testing for Parvo B19
PCR
IgM may aid with Dx
Positive IgG excludes Dx except in the context of HIV/SCID
1st line Tx of PRCA
Steroids+-
CsA
Time to response in PRCA
Usually 2-3 months after initiation of Tx
Duration of Tx in PRCA
1-2 months after normalization of Hb
(total of 3-6 months)
CsA effectiveness in PRCA
70-80% ORR
Maintenance Tx in PRCA
Low dose CsA
Combination with steroids improves relapse free survival
1st line Tx of PRCA when CsA contraindications
Cyclophosphamide or MTX +- Steroids
CY effectiveness in PRCA
40-60%
Median time of 12 weeks
Tx not exceeding 6 months
Mainly effective in LGL associated PRCA
MTX in T-LGL associated PRCA
Less effective than CY
Causes anemia
Mainly effective in T-LGL with neutropenia
Thymoma frequency in PRCA
30%
PRCA frequency in thymoma
5-7%
2nd line Tx for PRCA
Alemtuzumab
Anti-CD52
low dose of 10mg for 10 days or 10 mg 1/w for 4/8 weeks
PCP HSV prophylaxis
IVIG before Tx if hypogamma
2nd line Tx for PRCA- other options
Sirolimus
ORR 80% in 2nd line
ORR 90% in 1st line (eg. CKD pts)
Tx of PRCA in RA pts
Tofacitinib
Tx of PRCA in CLL pts
Rituximab
Tx of PRCA in MGUS pts
Bortezomib
Rituximab (if IgM)
PRCA developing in low risk MDS on EPO
May be due to Ab to EPO
Related ro SC administration of some products